Patients

At Satellos, our mission is to develop new medicines that restore muscle regeneration for people living with muscle diseases. Our potential treatment, SAT-3247, is focused on Duchenne muscular dystrophy — a condition where the body’s natural ability to repair muscle is severely impaired. We’re advancing our science with urgency and care, always focused on delivering meaningful results for the individuals and families affected by Duchenne.

We have completed our first-in-human Phase 1a/b clinical trial evaluating SAT-3247 in Healthy Volunteers and Adults with Duchenne, and have initiated a long-term follow-up study for patients that participated in that trial.

SAT-3247 is an oral treatment we’re developing to help improve how muscle repairs itself in people with Duchenne. The loss of dystrophin disrupts a key signal that guides muscle stem cells to respond to damage. SAT-3247 is designed to restore that signal by targeting a protein called AAK1. By doing so, it helps muscle stem cells divide and function more effectively — supporting the body’s natural ability to repair and rebuild muscle. This approach has the potential to benefit many people living with Duchenne, no matter their specific genetic mutation or severity of disease.

A family’s long-awaited joy turned to heartbreak when their young son was diagnosed with Duchenne muscular dystrophy. Through determination, hope, and the promise of science, they’ve found a path forward — but questions remain about what the future will hold. Read their story of love, resilience, and daring to dream of a different outcome.